Office:	3636 Blvd. of the Allies
	Pittsburgh, PA 15213
Phone:	412-209-7320
Fax:	412-209-7325
E-mail:	jkiss@itxm.org

Education
	AB, Boston University, Boston, MA, 1974
	M.D., Georgetown University, Washington, DC, 1978

Training
	Internship, University of Pittsburgh, Pittsburgh, PA, 1979
	Residency and Chief Resident/Residency, University of Pittsburgh, Pittsburgh, PA, 1982
	Hematology/Oncology Fellowship, Hospital of the University of PA, Philadelphia,PA, 1985
	Blood Banking Fellowship, Central Blood Bank of Pittsburgh, 1986

As a clinical investigator, Dr. Kiss has been the recipient of federal funding for the past 13 years as a member/grantee of several NHLBI-sponsored research programs, including the Transfusion Medicine Hemostasis/Thrombosis Clinical Trials Network (TMH-CTN), and REDS-II and III programs [REDS is an acronym for Retrovirus(REDS-II) or Recipient (REDS-III) Epidemiology in Donors Study], and through the RO1 award mechanism (STRIDE-Strategies to Reduce Iron Deficiency). His research interests include studies in thrombotic microangiopathies, particularly thrombotic thrombocytopenic purpura (TTP). He served as protocol lead/PI on the multicenter Study of TTP and Rituximab (STAR) trial in 2009. Although the trial was closed early, the study was innovative in its design to utilize immunotherapy (rituximab) up front in a randomized controlled trial in acquired (autoimmune) TTP that has served as a template for other non- randomized studies performed successfully in Europe. He is continuing his research work in TTP as a site PI for caplacizumab, a novel heavy chain monoclonal antibody that blocks VonWillebrand A1domain-platelet receptor Ib binding. He is also pursuing therapies for other thrombotic microangiopathies, such as “TAMOF”, or Thrombocytopenia-associated Multiorgan Failure, with plans for designing a randomized pilot trial utilizing plasma exchange.

Dr. Kiss also has been active in studying factors associated with the development of iron-deficiency and the effectiveness of low dose iron supplementation for this condition, utilizing blood donors as a research model. He served as a coinvestigator and leader of the laboratory substudy on the REDS-II Iron Study Evaluation (RISE), a multicenter observational study that redefined the prevalence of and risk factors for iron deficiency in US blood donors. This trial led to the pivotal Hemoglobin and Iron Recovery Study (HEIRS), a randomized controlled trial of low dose iron supplementation in blood donors. The primary results of this study were published in JAMA in 2015. Several ancillary studies are now being analyzed and prepared for publication, including a study quantifying iron compartments in blood donors and a study of iron biomarkers, including hepcidin and erythropoietin in relation to iron and hemoglobin recovery. In addition, Dr. Kiss has served as the site-PI on the STRIDE-Strategies to Reduce Iron Deficiency study, which tested several operational approaches to improve the compromised iron status of blood donors, including measurement and notification of ferritin levels and the use of two different iron formulations taken over a two year period of regular blood donation. Ancillary operational and iron quantification studies are also being published in relation to this trial.

For my complete bibliography, Click Here.

Selected Publications: